SMS PHARMACEUTICALS LTD.
SMSPHARMA · General/Diversified · NSE
₹397
Current Market Price
Fair Value (DCF)
₹123
Margin of Safety
-69.0%
Updated just now
YieldIQ Score
53/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
19%
ROE
—
Debt/Equity
0.44
WACC
11.1%
Market Cap
₹3,715 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.3%
Return on capital employed
EV / EBITDA
23.5×
Enterprise multiple
Debt / EBITDA
1.8×
Leverage vs earnings
Interest Coverage
6.3×
EBIT covers interest
Current Ratio
1.71×
Short-term liquidity
Asset Turnover
0.68×
Revenue per ₹ of assets
Revenue CAGR (3Y)
14.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹396.7
Bear case
₹69.1
MoS -474.1%
Base case
₹122.92
MoS -222.7%
Bull case
₹160.5
MoS -147.2%
Ratio Trends
SMSPHARMA · last 8 annual periods
ROE
10.8%
ROCE
15.2%
Operating Margin
—
Debt / Equity
0.49×
PE
87.7×
EV / EBITDA
11.5×
Historical Financials
SMSPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹563 Cr | ₹520 Cr | ₹520 Cr | ₹706 Cr | ₹779 Cr | +8.5% |
| EBITDA | — | ₹119 Cr | ₹58.5 Cr | ₹120 Cr | ₹144 Cr | +4.9% |
| EBIT | ₹102 Cr | ₹87.4 Cr | ₹16.5 Cr | ₹27.3 Cr | — | -28.1% |
| PAT | ₹62.5 Cr | ₹62.2 Cr | ₹6.2 Cr | ₹49.8 Cr | ₹69.1 Cr | +2.5% |
| EPS (diluted) | ₹7.39 | ₹7.35 | ₹0.00 | ₹2.04 | — | -27.5% |
| CFO | ₹106 Cr | ₹40.2 Cr | ₹22.4 Cr | ₹50.1 Cr | ₹81.7 Cr | -6.4% |
| CapEx | — | — | — | — | ₹-123 Cr | — |
| FCF | — | — | — | — | ₹-41.7 Cr | — |
| Total Assets | — | ₹860 Cr | ₹880 Cr | ₹1034 Cr | ₹1153 Cr | +7.6% |
| Total Debt | — | — | ₹131 Cr | ₹158 Cr | ₹311 Cr | +24.0% |
| Shareholders' Equity | — | — | ₹461 Cr | ₹536 Cr | ₹640 Cr | +8.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SMSPHARMA vs 4 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SENORES SENORES | — | — | Pending | 7.2% | — |
| SAIPARENT SAIPARENT | — | — | Pending | 15.9% | — |
| NGLFINE NGLFINE | — | — | Pending | 7.5% | — |
| TTKHLTCARE TTKHLTCARE | — | — | Pending | 7.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SMSPHARMA in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SMSPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SMSPHARMA →
Compare
Head-to-head with peers
Compare SMSPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SMSPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.